Showing results (171-180 of 219) with videos related to
Sort By:
Pageof 22
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 23, 2025
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief ReportXiuning Le, Christina Baik, Byoung Chul Cho, et al.Nature Communications|June 14, 2022
Automated detection and segmentation of non-small cell lung cancer computed tomography imagesSergey P Primakov, Abdalla Ibrahim, Janita E van Timmeren, et al.Frontiers in Oncology|May 22, 2023
Association of RANKL and EGFR gene expression with bone metastases in patients with metastatic non-small cell lung cancerAnita J W M Brouns, Lizza E L Hendriks, Iris J Robbesom-van den Berge, et al.British Journal of Clinical Pharmacology|August 10, 2021
Hyperhydration with cisplatin does not influence pemetrexed exposureNikki de Rouw, Hieronymus J Derijks, Luuk B Hilbrands, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2026
Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic TherapiesJonas Willmann, Edward Christopher Dee, Lizza E L Hendriks, et al.Eclinicalmedicine|May 1, 2023
Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancerG D Marijn Veerman, Rene J Boosman, Merel Jebbink, et al.Lung Cancer (Amsterdam, Netherlands)|October 18, 2025
Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer GroupMariana Brandão, Elena Prisciandaro, Eleni Xenophontos, et al.Molecular Oncology|May 31, 2021
NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatmentEstela Sánchez-Herrero, Roberto Serna-Blasco, Vadym Ivanchuk, et al.JAMA Oncology|June 4, 2021
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized TrialSalma K Jabbour, Ki Hyeong Lee, Nikolaj Frost, et al.Cancers|May 6, 2020
Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC PatientsElba Marin, Cristina Teixido, Elena Carmona-Rocha, et al.Pageof 22